MacroGenics (MGNX) Given Coverage Optimism Rating of 0.05

Headlines about MacroGenics (NASDAQ:MGNX) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. MacroGenics earned a news sentiment score of 0.05 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.7052787605683 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media headlines that may have effected Accern’s rankings:

A number of equities research analysts have weighed in on the stock. BidaskClub raised shares of MacroGenics from a “hold” rating to a “buy” rating in a report on Thursday, March 8th. Morgan Stanley reissued an “equal weight” rating and set a $26.00 target price (up from $18.00) on shares of MacroGenics in a report on Wednesday, March 14th. HC Wainwright started coverage on shares of MacroGenics in a research note on Monday, March 5th. They issued a “buy” rating and a $38.00 price objective on the stock. ValuEngine raised shares of MacroGenics from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Finally, TheStreet raised shares of MacroGenics from a “d” rating to a “c+” rating in a research note on Tuesday, March 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $30.25.



NASDAQ:MGNX opened at $23.91 on Thursday. MacroGenics has a 52 week low of $14.36 and a 52 week high of $32.74.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported $2.80 EPS for the quarter, beating the Zacks’ consensus estimate of $2.58 by $0.22. MacroGenics had a negative net margin of 12.44% and a negative return on equity of 8.22%. The company had revenue of $152.36 million for the quarter, compared to analyst estimates of $152.59 million. research analysts forecast that MacroGenics will post -4.42 EPS for the current year.

In related news, VP Lynn Cilinski sold 23,967 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $25.01, for a total transaction of $599,414.67. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Eric Blasius Risser sold 1,000 shares of the business’s stock in a transaction on Monday, March 12th. The shares were sold at an average price of $31.08, for a total transaction of $31,080.00. Following the transaction, the senior vice president now owns 10,100 shares in the company, valued at approximately $313,908. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 42,967 shares of company stock worth $1,098,005. Insiders own 8.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “MacroGenics (MGNX) Given Coverage Optimism Rating of 0.05” was first published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://dakotafinancialnews.com/2018/04/12/macrogenics-mgnx-given-coverage-optimism-rating-of-0-05.html.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers.

Insider Buying and Selling by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply